Kolon TissueGene Faces Delisting In Korea On Invossa Uncertainties

 
• By Jung Won Shin

Kolon TissueGene is facing delisting in South Korea after the recent revocation of approval of gene therapy Invossa, which could fuel legal action from shareholders. The company still hopes to resume Invossa trials in the US by submitting additional data demanded by the FDA.

Stock Market Down - Illustration
Kolon Life Shares Drop 22% On Decision To Delist Kolon TissueGene • Source: Shutterstock

More from South Korea

More from Focus On Asia